A
OKUR

Abingworth’s OnKure Therapeutics OKUR Stock Holding History

Abingworth’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$4.83M Hold
207,396
– – 1.57% 7
2022
Q3 		$6.95M Hold
207,396
– – 2.38% 7
2022
Q2 		$5.41M Hold
207,396
– – 1.73% 10
2022
Q1 		$6.08M Hold
207,396
– – 1.72% 9
2021
Q4 		$17.7M Hold
207,396
– – 4.3% 8
2021
Q3 		$15.3M Buy
207,396
+11,174
+6% +$948K 3.47% 7
2021
Q2 		$18.2M Buy
+196,222
New +$21.9M 5.62% 6

Other funds holding OKUR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Abingworth's OKUR Position: Q4 2022 in Review

Abingworth held its OnKure Therapeutics (OKUR) position steady in Q4 2022 at 207,396 shares worth $4.83M. The position accounts for 1.57% of the portfolio, ranked #7.

Abingworth first reported a position in OKUR in Q2 2021 and has held it in 7 quarters since. The position peaked at $18.2M in Q2 2021. 32 funds tracked by Wall St. Rank hold OKUR as of Q4 2022.

  • Abingworth held 207,396 shares of OnKure Therapeutics worth $4.83M as of Q4 2022.
  • Abingworth left its OnKure Therapeutics share count unchanged in Q4 2022.
  • OnKure Therapeutics made up 1.57% of Abingworth's portfolio in Q4 2022, its #7 holding.
  • Abingworth first reported a position in OnKure Therapeutics in Q2 2021 and has held it in 7 quarters since.
  • Abingworth's OnKure Therapeutics position peaked at $18.2M in Q2 2021.
  • 32 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q4 2022.

Based on Abingworth's 13F filing for Q4 2022, filed 10 Feb 2023.